Fig. 2

A–J. (A) Overview of the experimental design of the female BALB/c mice model of ovalbumin (OVA)-induced allergic airway inflammation. (B) Body weights remained stable in all groups over the 21 days. (C) Lung and (D) spleen weight comparison between the groups showing a significant weight increase in the lungs and spleens of the Vehicle/OVA (VO, n = 5), group compared to the TH1579/OVA (TO, n = 6), dexamethasone/OVA (DO, n = 6), TH1579/PBS (TP, n = 4), and vehicle/PBS (VP, n = 3) groups. (E) Total protein concentration in the bronchoalveolar lavage (BAL) fluid. Lower protein levels were observed in the TH1579 and dexamethasone treated groups compared to mice only receiving vehicle. Quantification of the following antibodies in plasma using ELISA specific for; (F) total IgE, (G) OVA-specific IgE, (H) total IgG, (I) OVA-specific IgG, and (J) OVA-specific IgG1. Mice treated with the MTH1-inhibitor TH1579 had lower levels of total IgE, OVA-specific IgE, OVA-specific IgG and OVA-specific IgG1 compared to the VO-group. The results are displayed as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Dunnett’s post hoc test (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05)